Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Nektar rapeutics

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

Benzinga · Aug 8, 2022

Expert Ratings for Nektar Therapeutics

Within the last quarter, Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings:

Benzinga · May 31, 2022

Nektar Therapeutics's Return On Capital Employed Insights

According to Benzinga Pro data, during Q1, Nektar Therapeutics (NASDAQ:NKTR) posted sales of $24.82 million. Earnings were up 37.94%, but Nektar Therapeutics still reported an overall loss of $90.39 million.

Benzinga · May 31, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

68 Biggest Movers From Yesterday

Gainers Casa Systems, Inc. (NASDAQ: CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core network functions.

Benzinga · Apr 19, 2022

Mid-Afternoon Market Update: Crude Oil Rises Over 1%; Nektar Therapeutics Shares Slide

U.S. stocks traded higher in volatile session, with the Dow Jones gaining around 60 points toward the end of trading on Monday.

Benzinga · Apr 18, 2022

Mid-Day Market Update: U.S. Stocks Turn Lower; Bank of America Earnings Top Views

U.S. stocks turned lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday.

Benzinga · Apr 18, 2022

34 Stocks Moving In Monday's Mid-Day Session

Gainers Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions.

Benzinga · Apr 18, 2022

Read news from The Economist, FT, and more,
with one subscription

Why Nektar Shares Are Down Almost 35%

Shares of Nektar Therapeutics (NASDAQ: NKTR) have come under pressure after the company “announced the discontinuation of the remaining clinical development programs of bempeg + nivo (Opdivo) in collaboration with Bristo,” according to BofA Securities.

Benzinga · Apr 18, 2022

Stocks That Hit 52-Week Lows On Monday

On Monday, 466 companies hit new 52-week lows.

Benzinga · Apr 18, 2022

Mid-Morning Market Update: Markets Open Higher; Dow Gains 100 Points

U.S. stocks traded higher this morning, with the Dow Jones adding around 100 points on Monday.

Benzinga · Apr 18, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022

Upgrades

Benzinga · Apr 18, 2022

Expert Ratings for Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter:

Benzinga · Apr 18, 2022

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers

Benzinga · Apr 14, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022

Upgrades

Benzinga · Mar 15, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Feb 25, 2022

Earnings Outlook For Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts estimate that Nektar Therapeutics will report an earnings per share (EPS) of $-0.81.

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.